Delivering record annual sales and profits according to preliminary financial results, Slovenia’s Krka will soon look to set up shop in India via a new company established with local big player Laurus Labs.

Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.

Slovenia’s Krka enjoyed a solid year for its dominant Prescription Pharmaceuticals business, with sales climbing by 7% on the back of growth for all six of its geographic business units.

Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.